`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`MDL NO. 22-MD-3038 (CFC)
`
`ANDA CASE
`
`
`
`
`C.A. No. 22-294 (CFC)
`CONSOLIDATED
`ANDA CASE
`
`
`
`
`)
`)
`)
`)
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`))))))))
`
`
`
`IN RE: OZEMPIC
`(SEMAGLUTIDE)
`PATENT LITIGATION
`
`Plaintiffs,
`
`
`
`v.
`
`
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`
`
`
`
`RIO BIOPHARMACEUTICALS
`INC., et al.,
`
`
`
`
`
`
`Defendants.
`
`
`
`DR. REDDY’S LABORATORIES, LTD.’S AND DR. REDDY’S
`LABORATORIES, INC.’S STIPULATION CONCERNING
`INVALIDITY GROUNDS
`
`Defendants Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.
`
`(collectively, “DRL”) submit this stipulation concerning its invalidity grounds.
`
`On October 20, 2023, DRL filed petition number IPR2024-00009 with the
`
`Patent Trial and Appeal Board (“PTAB”) requesting inter partes review of U.S.
`
`Patent No. 10,335,462 (“the ’462 patent”) (the “Petition”) and joinder to IPR2023-
`
`00724 (“the Mylan IPR”). The Petition asserted the same grounds of invalidity as
`
`the Mylan IPR:
`
`
`
`1
`
`Novo Nordisk Exhibit 2541
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`Case 1:22-md-03038-CFC Document 334 Filed 05/03/24 Page 2 of 3 PageID #: 5701
`
`Novo Nordisk Exhibit 2541
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`Case 1:22-md-03038-CFC Document 334 Filed 05/03/24 Page 3 of 3 PageID #: 5702
`
`
`
`HEYMAN ENERIO
`GATTUSO & HIRZEL LLP
`
`/s/ Dominick T. Gattuso
`Dominick T. Gattuso (#3630)
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(302) 472-7300
`dgattuso@hegh.law
`
`Attorneys for Defendants Dr.
`Reddy’s Laboratories, Ltd. and Dr.
`Reddy’s Laboratories, Inc.
`
`
`
`
`
`
`
`OF COUNSEL:
`
`Jovial Wong
`Sharon Lin
`WINSTON & STRAWN LLP
`1901 L Street N.W.
`Washington DC 20036
`(202) 282-5000
`jwong@winston.com
`slin@winston.com
`
`George C. Lombardi
`Alison M. King
`WINSTON & STRAWN LLP
`35 W. Wacker Drive
`Chicago, IL 60601-9703
`Phone: (312) 558-5600
`glombardi@winston.com
`amking@winston.com
`
`
`Dated: May 3, 2024
`
`
`
`3
`
`Novo Nordisk Exhibit 2541
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`